Sana Biotechnology (NASDAQ:SANA) Stock Jumps 5.9% – Here’s What Happened

Shares of Sana Biotechnology, Inc. (NASDAQ:SANA – Get Free Report) shot up 5.9% during trading on Wednesday. The stock traded as high as $1.95 and last traded at $1.9910. Approximately 166,184 shares were traded during trading, a decline of 95% from the average session volume of 3,160,180 shares. The stock had previously closed at $1.88.

Analyst Ratings Changes

Several research firms recently commented on SANA. Weiss Ratings lowered shares of Sana Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, November 11th. Wall Street Zen upgraded shares of Sana Biotechnology from a “sell” rating to a “hold” rating in a research note on Saturday, November 7th. Citigroup lowered their price target on shares of Sana Biotechnology to $11.00 and set a “buy” rating on the stock in a report on Monday. Bank of America reduced their price objective on Sana Biotechnology from $7.00 to $6.00 and set a “buy” rating on the stock in a research note on Friday, August 14th. Finally, TD Cowen raised shares of Sana Biotechnology to a “strong-buy” rating in a report on Monday, August 24th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Sana Biotechnology presently has a consensus rating of “Moderate Buy” and an average target price of $9.83.

Read Our Latest Analysis on Sana Biotechnology

Sana Biotechnology Stock Down 5.9%

The firm has a 50 day moving average of $2.59 and a two-hundred day moving average of $3.23. The firm has a market capitalization of $521.37 million, a price-to-earnings ratio of -3.28 and a beta of 2.30.

Sana Biotechnology (NASDAQ:SANA – Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.01. Sell-side analysts forecast that Sana Biotechnology, Inc. will post -0.51 EPS for the current fiscal year.

Institutional Trading of Sana Biotechnology

Several hedge funds and other institutional investors have recently bought and sold shares of SANA. Allworth Financial LP grew its holdings in Sana Biotechnology by 880.8% in the third quarter. Allworth Financial LP now owns 13,123 shares of the company’s stock worth $38,000 after purchasing an additional 11,785 shares during the period. Aquatic Capital Management LLC bought a new stake in shares of Sana Biotechnology in the 3rd quarter worth about $548,000. Goldman Sachs Group Inc. grew its position in shares of Sana Biotechnology by 13.2% during the 3rd quarter. Goldman Sachs Group Inc. now owns 2,680,550 shares of the company’s stock worth $7,814,000 after buying an additional 312,615 shares in the last quarter. Toronto Dominion Bank grew its stake in Sana Biotechnology by 0.3% in the third quarter. Toronto Dominion Bank now owns 1,978,964 shares of the company’s stock valued at $5,769,000 after purchasing an additional 6,583 shares during the last quarter. Finally, Palumbo Wealth Management LLC raised its stake in Sana Biotechnology by 39.6% in the third quarter. Palumbo Wealth Management LLC now owns 83,462 shares of the company’s stock valued at $243,000 after buying an additional 23,689 shares during the last quarter. Institutional investors own 88.23% of the company’s stock.

Sana Biotechnology Company Profile

(Get Free Report)

Sana Biotechnology, Inc. is a clinical-stage biotechnology company founded in 2018 and headquartered in Seattle. It develops engineered cells intended to treat a range of diseases, including cancer, autoimmune disorders and conditions that may be addressed through cell replacement. The company’s research focuses on modifying cells to improve their therapeutic properties, including approaches designed to help transplanted cells evade immune rejection. Its programs include engineered immune-cell therapies and cell-replacement treatments, such as work involving insulin-producing cells for type 1 diabetes.

Read More

Receive News & Ratings for Sana Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sana Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.